Results 81 to 90 of about 261,105 (346)

Membrane Fusion‐Inspired Nanomaterials: Emerging Strategies for Infectious Disease and Cancer Diagnostics

open access: yesAdvanced Healthcare Materials, EarlyView.
Membrane fusion‐inspired nanomaterials offer transformative potential in diagnostics by mimicking natural fusion processes to achieve highly sensitive and specific detection of disease biomarkers. This review highlights recent advancements in nanomaterial functionalization strategies, signal amplification systems, and stimuli‐responsive fusion designs,
Sojeong Lee   +9 more
wiley   +1 more source

Long Non-coding RNA CDKN2B Antisense RNA 1 Gene Contributes to Paclitaxel Resistance in Endometrial Carcinoma

open access: yesFrontiers in Oncology, 2019
Endometrial cancer (EC) is the most common malignancy of the female reproductive tract. In this study, we clarified the clinical significance of CDKN2B antisense RNA 1 (CDKN2B-AS) gene, and its effects on paclitaxel sensitivity in EC.
Chao Shang   +3 more
doaj   +1 more source

El Paclitaxel

open access: yesRevista de Química, 2015
Actualmente, el cáncer es una causa importante de mortalidad en el mundo. El paclitaxel es un fármaco que actúa de forma eficiente frente a un gran número de tipos de cáncer y se obtiene, principalmente, a partir de especies de tejo (Taxus spp.), un árbol de la familia de las taxáceas.
Barrales-Cureño, Hebert Jair   +2 more
openaire   +2 more sources

Novel Drug‐Testing Platform for Vascular Injury‐induced Intimal Hyperplasia Using a Microphysiological System

open access: yesAdvanced Healthcare Materials, EarlyView.
This study develops a 3D vascular injury model using a microphysiological system that mimics key features of intimal hyperplasia. Antiproliferative drugs reduced VSMC proliferation but worsened endothelialdenudation. A combination of diphenyleneiodonium and quercetin effectively reduced proliferation and migration of VSMC and inflammation while ...
Ungsig Nam   +7 more
wiley   +1 more source

Albumin-bound paclitaxel in solid tumors: clinical development and future directions

open access: yesDrug Design, Development and Therapy, 2015
Madappa N Kundranda,1 Jiaxin Niu21Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, 2Department of Medical Oncology, Cancer Treatment Centers of America, Goodyear, Arizona, USA Abstract: Albumin-bound paclitaxel (nab-paclitaxel) is a solvent ...
Kundranda MN, Niu J
doaj  

Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis

open access: yesArtificial Cells, Nanomedicine, and Biotechnology, 2019
Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) offer more efficient paclitaxel delivery into tumor cells with fewer side effects than conventional chemotherapies.
Hong Tan, Jing Hu, Shan Liu
doaj   +1 more source

Electroacupuncture Alleviates Paclitaxel-Induced Peripheral Neuropathic Pain in Rats via Suppressing TLR4 Signaling and TRPV1 Upregulation in Sensory Neurons

open access: yesInternational Journal of Molecular Sciences, 2019
Paclitaxel-induced peripheral neuropathy is a common adverse effect during paclitaxel treatment resulting in sensory abnormalities and neuropathic pain during chemotherapy and in cancer survivors.
Yuanyuan Li   +10 more
semanticscholar   +1 more source

Mesoporous Bioactive Glasses: A Powerful Tool in Tissue Engineering and Drug Delivery

open access: yesAdvanced Healthcare Materials, EarlyView.
This work is a comprehensive revision of bioactive glasses (BGs), pioneered by Prof. L.L. Hench, which are key in bone repair and regenerative medicine. Sol–gel methods and mesoporous designs enhanced their bioactivity, ions, and drug delivery. BGs now support gene therapy and 3D‐printed scaffolds, enabling personalized, multifunctional treatments in ...
Natividad Gómez‐Cerezo   +3 more
wiley   +1 more source

Paclitaxel in Breast Cancer

open access: yesWomen's Health, 2006
Paclitaxel, a chemotherapeutic drug isolated from the Pacific yew, was approved for the treatment of metastatic breast cancer in 1994 and remains one of the most important agents in the treatment of patients with this disease. It is currently approved for the adjuvant treatment of node-positive breast cancer, administered sequentially after a standard
Sharon H. Giordano   +2 more
openaire   +3 more sources

Phase I Study of Emactuzumab Single Agent or in Combination with Paclitaxel in Patients with Advanced/Metastatic Solid Tumors Reveals Depletion of Immunosuppressive M2-like Macrophages.

open access: yesAnnals of Oncology, 2019
BACKGROUND Emactuzumab is a monoclonal antibody against the colony-stimulating factor (CSF)-1 receptor and targets tumor-associated macrophages (TAMs). This study assessed the safety, clinical activity, pharmacokinetics (PK) and pharmacodynamics (PD) of ...
C. Gomez-Roca   +25 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy